Generics - Generics, Dermatologicals

Filter

Current filters:

GenericsDermatologicals

Popular Filters

Akorn to acquire VersaPharm for $440 million

Akorn to acquire VersaPharm for $440 million

10-05-2014

Following swiftly on its completion of the acquisition of Hi-Tech Pharmacal (Nasdaq: HITK) for $640 million…

AkornDermatologicalsGenericsMergers & AcquisitionsVersaPharm

Abraaj sells stake in Opalia Pharma to Recordati

05-11-2013

The Dubai-based Abraaj Group, an investor operating in global growth markets, has announced its full…

Abraaj GroupDermatologicalsGastro-intestinalsGenericsMergers & AcquisitionsOpalia PharmaRecordatiRespiratory and PulmonaryRest of the World

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

News briefs: Dr Reddy's launches generic Accutane; Cyprus drug shortages

29-03-2013

Indian drugmaker Dr Reddy's Laboratories (NYSE: RDY) says it launched Zenatane (isotretinoin capsules…

AccutaneDermatologicalsDr Reddy's LaboratoriesEuropeGenericsHealthcareMarkets & MarketingNorth AmericaPharmaceuticalZenatane

Briefs: Glenmark challenges Bayer patent; FDA delays Merck & Co's sugammadex

18-03-2013

Indian drugmaker Glenmark Generics confirms that it seeking US Food and Drug Administration approval…

BayerBridionDermatologicalsFinacea GelGenericsGlenmark PharmaceuticalsMerck & CoNeurologicalNorth AmericaPatentsPharmaceuticalRegulationsugammadex

Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study

10-02-2013

Ireland-based drugmaker Shire (LSE: SHP) says it has settled all pending litigation with Impax Laboratories…

ABH001Adderall XRDermatologicalsGenericsImpax LaboratoriesLegalNeurologicalNorth AmericaPharmaceuticalResearchShire

Ranbaxy Labs' Absorica debuts in USA

27-11-2012

Indian drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan's Daiichi Sankyo, said…

AbsoricaCipher PharmaceuticalsDaiichi SankyoDermatologicalsGalephar Pharmaceutival ResearchGenericsMarkets & MarketingNorth AmericaPharmaceuticalRanbaxy Laboratories

Shire's Dermagraft cleared in Canada; settles Intuniv litigation

06-09-2012

Ireland headquartered Shire (LSE: SHP), NASDAQ: SHPG) says that its lead regenerative medicine product,…

Anchen PharmaceuticalsDermagraftDermatologicalsDiabetesGenericsIntunivNeurologicalNorth AmericaPatentsPharmaceuticalRegulationShireTWi Pharmaceuticals

Watson confirms patent challenges for Xopenox HFA and Epiduo Gel

31-07-2012

US generics drugmaker Watson Pharmaceuticals NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories…

Dainippon Sumitomo PharmaDermatologicalsEpiduo GelGaldermaGenericsLegalNorth AmericaRegulationRespiratory and PulmonarySunovionWatson PharmaceuticalsXopenox

US FTC puts conditions on Novartis buy of Fougera

17-07-2012

The USA's Federal Trade Commission said yesterday that it will require Swiss drug major drug Novartis…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalTolmar

Hi-Tech Pharmacal gains rights to the Cormax brand from Watson

05-06-2012

Hi-Tech Pharmacal (Nasdaq: HITK) says it has signed a definitive agreement under which it has acquired…

CormaxDermatologicalsGenericsHi-Tech PharmacalLicensingWatson Pharmaceuticals

Suneva Medical acquires product portfolio from Spear Pharma

24-05-2012

Privately-held US aesthetics company Suneva Medical has acquired an aesthetic product portfolio from…

DermatologicalsGenericsMergers & AcquisitionsPharmaceuticalRefissaSpear PharmaceuticalsSuneva MedicalTretinoin

Novartis to buy US generic derma company Fougera for over $1.5 billion

03-05-2012

Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its…

DermatologicalsFougera PharmaceuticalsGenericsMergers & AcquisitionsNovartisPharmaceuticalSandoz

USA’s SOHM acquires Novatrend to expand presence in India

28-11-2011

California, USA-based generic drugmaker SOHM (Pinksheets: SHMN) has announced the acquisition of business…

Asia-PacificDermatologicalsGenericsMergers & AcquisitionsNovatrend MedicamentPharmaceuticalSOHM

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top